QIAGEN and Celera Establish Distribution Agreement for Respiratory Pathogen Panel
Advertisement
QIAGEN N.V. and Celera Corporation announced an agreement under which QIAGEN will distribute a Celera molecular multiplex assay. The assay is the next generation version of QIAGEN's ResPlex II assay for detection of respiratory pathogens. Multiplex assays allow testing for a multiple number of different pathogens in a single run. Financial details were not disclosed.
Under the terms of the agreement, QIAGEN has the exclusive worldwide rights to distribute this multiplex test kit, which will be manufactured by Celera. The new ResPlex assay detects 19 different pathogens associated with respiratory infections and is designed for use with LiquiChip (Luminex) 100 and 200 instrument platforms.